ARTA
KDNY

A.R.T. Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

A.R.T. Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,390
Closed -$79K – 1125
2019
Q4 		$79K Buy
13,390
+4,340
+48% +$23.6K ﹤0.01% 1231
2019
Q3 		$48K Sell
9,050
-4,180
-32% -$27.7K ﹤0.01% 1321
2019
Q2 		$102K Buy
13,230
+4,421
+50% +$67.3K 0.01% 1190
2019
Q1 		$175K Sell
8,809
-11,917
-57% -$208K 0.01% 1096
2018
Q4 		$274K Buy
+20,726
New +$414K 0.02% 958
2017
Q4 		– Sell
-11,080
Closed -$590K – 1750
2017
Q3 		$590K Buy
11,080
+7,880
+246% +$468K 0.03% 769
2017
Q2 		$182K Buy
+3,200
New +$161K 0.01% 1180
2016
Q2 		– Sell
-9,538
Closed -$610K – 1708
2016
Q1 		$610K Buy
+9,538
New +$771K 0.03% 780

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

A.R.T. Advisors's KDNY Position: Q1 2020 in Review

A.R.T. Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2020, closing a stake of 13,390 shares — an estimated $79K sold.

A.R.T. Advisors first reported a position in KDNY in Q1 2016 and held it in 8 quarters. The position peaked at $610K in Q1 2016. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2020.

  • A.R.T. Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 13,390 Chinook Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $79K.
  • A.R.T. Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 8 quarters.
  • A.R.T. Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $610K in Q1 2016.
  • 82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.